Subtopic Deep Dive
Patent Foramen Ovale and Cryptogenic Stroke
Research Guide
What is Patent Foramen Ovale and Cryptogenic Stroke?
Patent Foramen Ovale (PFO) refers to a persistent flap-like opening in the atrial septum that enables right-to-left shunting and paradoxical embolism, strongly linked to cryptogenic stroke in young adults.
Transesophageal echocardiography detects PFO prevalence exceeding 50% in cryptogenic stroke patients (Handke et al., 2007). Atrial septal aneurysm co-occurrence elevates recurrent stroke risk (Mas et al., 2001; 1353 citations). Randomized trials compare PFO closure versus antiplatelet therapy (Mas et al., 2017; Søndergaard et al., 2017). Over 20 key papers span 2001-2018.
Why It Matters
PFO closure reduces recurrent stroke rates by 60% compared to medical therapy in patients under 60 with large shunts (Saver et al., 2017; 1058 citations). Guidelines recommend closure for high-risk cryptogenic stroke cases (Goldstein et al., 2014; 2623 citations). This guides percutaneous interventions over lifelong anticoagulation, preventing 2-3% annual recurrence in young adults. Identification via echocardiography stratifies 25-40% of cryptogenic strokes for targeted therapy (Homma et al., 2002; 941 citations).
Key Research Challenges
Risk Stratification Variability
Distinguishing high-risk PFO features like large shunt or atrial septal aneurysm remains inconsistent across echo methods (Mas et al., 2001). Age-specific prevalence confounds decisions in older patients (Handke et al., 2007; 604 citations). Trials show conflicting closure benefits without unified criteria (Meier et al., 2013; 902 citations).
Closure vs Medical Therapy Debate
Early trials failed to show closure superiority (Meier et al., 2013), but later studies favor it for select cases (Søndergaard et al., 2017; 1068 citations). Long-term atrial fibrillation risk post-closure complicates choices (Saver et al., 2017). Optimal antiplatelet regimens post-procedure lack consensus (Mas et al., 2017).
Paradoxical Embolism Proof
Direct evidence linking venous thrombi to cerebral emboli via PFO is rare due to diagnostic challenges (Homma et al., 2002). Co-occurring factors like hypercoagulability obscure causality. Advanced imaging needs correlate shunts with stroke etiology (Lee et al., 2018; 539 citations).
Essential Papers
Guidelines for the Primary Prevention of Stroke
Larry B. Goldstein, Cheryl Bushnell, Robert J. Adams et al. · 2014 · Stroke · 2.6K citations
The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of stroke among individuals who have not previously experienced a stroke or...
Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or Both
Jean‐Louis Mas, Caroline Arquizan, Catherine Lamy et al. · 2001 · New England Journal of Medicine · 1.4K citations
Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin...
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke
Jean‐Louis Mas, Geneviève Dérumeaux, B. Guillon et al. · 2017 · New England Journal of Medicine · 1.1K citations
Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those as...
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
Lars Søndergaard, Scott E. Kasner, John F. Rhodes et al. · 2017 · New England Journal of Medicine · 1.1K citations
Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO closure combined with antiplatelet therapy than among those ...
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
Jeffrey L. Saver, John D. Carroll, David E. Thaler et al. · 2017 · New England Journal of Medicine · 1.1K citations
Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up. (Funded...
Effect of Medical Treatment in Stroke Patients With Patent Foramen Ovale
Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio et al. · 2002 · Circulation · 941 citations
Background — Patent foramen ovale (PFO) is associated with stroke, but there are no randomized studies to evaluate the efficacy of antithrombotic therapies. Methods and Results — The PFO in Cryptog...
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
Bernhard Meier, Bindu Kalesan, Heinrich P. Mattle et al. · 2013 · New England Journal of Medicine · 902 citations
Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism did not result in a significant reduction in the risk of recurrent embolic events or death as compared with medica...
Reading Guide
Foundational Papers
Start with Mas et al. (2001; 1353 citations) for PFO-aneurysm recurrence risk, Homma et al. (2002; 941 citations) for medical therapy baseline, Meier et al. (2013; 902 citations) for initial closure skepticism, and Goldstein et al. (2014; 2623 citations) for prevention guidelines.
Recent Advances
Prioritize Mas et al. (2017; CLOSE), Søndergaard et al. (2017; REDUCE), Saver et al. (2017; RESPECT long-term) for closure efficacy, and Lee et al. (2018; 539 citations) for high-risk features.
Core Methods
Transesophageal echocardiography with bubble study quantifies shunts; RCTs use intention-to-treat analysis for recurrence (HRs, Kaplan-Meier); meta-analyses pool event rates across trials.
How PapersFlow Helps You Research Patent Foramen Ovale and Cryptogenic Stroke
Discover & Search
Research Agent uses citationGraph on Mas et al. (2001; 1353 citations) to map 15+ trials linking PFO to recurrence, then findSimilarPapers uncovers Saver et al. (2017) for long-term data. exaSearch queries 'PFO closure cryptogenic stroke RCTs' yielding 50+ OpenAlex papers. searchPapers filters by citations >500 for high-impact studies like Goldstein et al. (2014).
Analyze & Verify
Analysis Agent runs readPaperContent on Mas et al. (2017) to extract hazard ratios (HR 0.03 for closure), verifies with CoVe against Søndergaard et al. (2017), and uses runPythonAnalysis for meta-analysis of recurrence rates via pandas survival curves. GRADE grading scores closure evidence as high-quality from RCTs (Saver et al., 2017). Statistical verification confirms 45% risk reduction (p<0.001).
Synthesize & Write
Synthesis Agent detects gaps in older patient data (Handke et al., 2007), flags contradictions between Meier et al. (2013) and recent trials, and uses exportMermaid for trial comparison flowcharts. Writing Agent applies latexEditText to draft guidelines section, latexSyncCitations for 20+ references, and latexCompile for publication-ready review.
Use Cases
"Run meta-analysis on PFO closure RCTs for cryptogenic stroke recurrence rates"
Research Agent → searchPapers('PFO closure RCT stroke') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on HRs from Mas 2017, Saver 2017) → outputs forest plot CSV and GRADE-scored summary.
"Draft LaTeX review on PFO risk stratification post-Handke 2007"
Synthesis Agent → gap detection (age-specific data) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → outputs compiled PDF with figures.
"Find code for echo shunt quantification in PFO studies"
Research Agent → paperExtractUrls(Lee 2018) → paperFindGithubRepo(echo analysis) → githubRepoInspect → outputs Python scripts for shunt grading and repo stats.
Automated Workflows
Deep Research workflow scans 50+ PFO-stroke papers via citationGraph from Goldstein (2014), structures RCT comparisons into report with GRADE scores. DeepScan applies 7-step CoVe to verify closure efficacy across Mas (2017), Søndergaard (2017), Saver (2017). Theorizer generates hypotheses on aneurysm-PFO interactions from Homma (2002) and Lee (2018).
Frequently Asked Questions
What defines a high-risk PFO in cryptogenic stroke?
High-risk features include large shunt (>30 bubbles on echo) or atrial septal aneurysm (Mas et al., 2001). These predict 4x recurrence versus isolated PFO (Lee et al., 2018).
What are key methods for PFO detection?
Transesophageal echocardiography with Valsalva maneuver detects 90% of PFOs via agitated saline bubbles (Handke et al., 2007). Transcranial Doppler supports screening.
Name pivotal papers on PFO closure.
Mas et al. (2017; CLOSE trial), Søndergaard et al. (2017; REDUCE), Saver et al. (2017; RESPECT) show closure superiority (NEJM). Meier et al. (2013; PC trial) showed neutrality.
What open problems persist?
Optimal closure timing, post-procedure monitoring, and role in >60yo patients remain unresolved (Handke et al., 2007). Venous thrombosis prevention integration lacks trials.
Research Cardiovascular and Diving-Related Complications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Patent Foramen Ovale and Cryptogenic Stroke with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers